The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.
Sruthi Katamneni, DDS, MBA, MHA
Advertisement
Articles by Sruthi Katamneni, DDS, MBA, MHA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Enlicitide Decanoate Data Show Significant LDL-C Reductions in At-Risk Patients
2
Newly Approved Specialty Drugs Advance Care for Inflammatory and Autoimmune Diseases
3
FDA Approves Tarlatamab-Dlle to Treat Adults With Extensive Stage Small Cell Lung Cancer
4
Twice-Yearly Depemokimab Improves Peak Expiratory Flow and Asthma Symptoms
5
